Krystal Biotech (KRYS) EBIAT (2021 - 2025)
Krystal Biotech (KRYS) has disclosed EBIAT for 5 consecutive years, with $51.4 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 13.02% to $51.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $204.8 million through Dec 2025, up 129.74% year-over-year, with the annual reading at $204.8 million for FY2025, 129.74% up from the prior year.
- EBIAT hit $51.4 million in Q4 2025 for Krystal Biotech, down from $79.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $80.7 million in Q3 2023 to a low of -$50.0 million in Q1 2022.
- Historically, EBIAT has averaged $4.8 million across 5 years, with a median of -$7.3 million in 2021.
- Biggest five-year swings in EBIAT: crashed 215.99% in 2022 and later surged 3734.01% in 2025.
- Year by year, EBIAT stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then surged by 127.12% to $8.7 million in 2023, then skyrocketed by 423.23% to $45.5 million in 2024, then increased by 13.02% to $51.4 million in 2025.
- Business Quant data shows EBIAT for KRYS at $51.4 million in Q4 2025, $79.4 million in Q3 2025, and $38.3 million in Q2 2025.